Young B-ALL patients who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range.
Scientists at City of Hope identified a protein that could help prevent CAR T-cell therapy antigen escape. The research, published in the journal Cell, could lead to more personalized therapies that improve cancer patients’ survival.
